hCG, or human chorionic gonadotropin, is a hormone studied mainly in fertility, reproductive medicine, and male hormonal protocols. The evidence base is large, including randomized trials, but results depend strongly on the condition, route, and protocol studied. Chia does not offer hCG treatment.
Not sure where to start? Take the 3-min clinical quiz.
See if you qualify →What it is
hCG stands for human chorionic gonadotropin. It is a hormone in the gonadotropin family and is commonly discussed in fertility care, assisted reproductive technology, ovulation induction, and male hormonal pharmacology; the supplied evidence includes human trials across these settings 1 3 4 10.
You may also see hCG described as human chorionic gonadotrophin, urinary human chorionic gonadotropin, recombinant human chorionic gonadotropin, or by brand names such as Pregnyl. In the supplied evidence set, both recombinant and urinary hCG were studied in men, while sublingual hCG was studied as an adjuvant to ovulation induction 3 10.
How hCG differs from GLP-1 medications and longevity peptides
hCG is not a GLP-1 medication. GLP-1 medicines such as semaglutide and tirzepatide act on incretin pathways involved in appetite and glucose signaling, while hCG is a reproductive hormone studied in fertility and hormone-response settings in the supplied records 1 4 10.
hCG is also different from longevity peptides such as sermorelin, NAD+, glutathione, and GHK-Cu. At Chia, we offer clinician-reviewed care for certain listed treatments, including semaglutide injection, tirzepatide tablets and injections, sermorelin, NAD+, glutathione, and GHK-Cu cream, but we do not offer hCG.
Where hCG is typically discussed
In the supplied PubMed records, hCG appears in studies of frozen embryo transfer, in vitro fertilization and embryo transfer, ovulation induction, controlled ovarian stimulation, endometrial immune signaling, pharmacokinetics in obese and normal-weight women, and male pharmacology 1 5 6 7 10 11.
Mechanism of action
Human chorionic gonadotropin has LH-like activity, meaning it can signal through reproductive hormone pathways that overlap with luteinizing hormone biology. The supplied evidence supports discussing hCG in reproductive-axis research, including ovarian stimulation, ovulation induction, endometrial signaling, and male pharmacology, but it does not make one mechanism equal to benefit for every patient or goal 4 6 7 10.
Mechanism is a starting point, not a treatment promise. For example, a human clinical trial studied hCG-related recruitment of regulatory T cells in the endometrium through chemokine CCL2, but that mechanism-focused record should not be read as proof that hCG improves every fertility endpoint 6.
In men, the supplied evidence includes a randomized controlled trial on the single- and multi-dose pharmacology of recombinant and urinary human chorionic gonadotrophin. That supports a narrow discussion of formulation and hormone-response pharmacology, not broad claims about symptoms, fertility, testosterone outcomes, or long-term safety outside the studied setting 10.
Evidence
Evidence grade: A. The supplied PubMed set includes more than 2 human randomized controlled trials, including studies in frozen embryo transfer, ovulation induction, ovarian stimulation, IVF support, pharmacokinetics, and male pharmacology 1 3 4 5 7 10 11.
The evidence is strongest as a map of where hCG has been studied, not as a single yes-or-no answer. Trials include ovulatory women undergoing frozen embryo transfer, women undergoing ovulation induction, women with clomiphene-resistant polycystic ovarian syndrome, controlled ovarian stimulation, obese and normal-weight women in pharmacokinetic research, and men in pharmacology research 1 3 4 7 10 11.
Fertility and assisted reproduction
hCG has been studied in assisted reproduction settings, including frozen embryo transfer in ovulatory women and hCG support after in vitro fertilization and embryo transfer 1 5. A separate clinical trial asked whether intrauterine hCG infusions should be used before embryo transfer, showing that embryo-transfer timing and route have been active research questions 8.
Ovulation induction and ovarian stimulation
The supplied records include a randomized controlled trial of sublingual human chorionic gonadotropin as an adjuvant to ovulation induction and a randomized trial involving hCG plus clomiphene citrate in women with clomiphene-resistant polycystic ovarian syndrome 3 4. Another randomized trial studied low-dose hCG alone to complete controlled ovarian stimulation 7.
Male pharmacology and hormone-response studies
For men, the supplied evidence includes a randomized controlled trial of single- and multi-dose pharmacology of recombinant and urinary hCG 10. If you are reading about hCG because of testosterone symptoms, it may help to first understand the broader hormone evaluation process in our guides to testosterone, low testosterone symptoms in men, and natural ways to support testosterone.
Specialized pediatric urology contexts
The supplied records also include specialized pediatric urology research. One clinical trial studied preoperative hCG treatment in infancy for proximal hypospadias and chordee, and another pediatric study examined the relationship between inhibin B and FSH levels in prepubertal boys with cryptorchidism 9 12.
What the evidence does not show
The supplied evidence does not support calling hCG a weight-loss medication. One randomized controlled trial studied hCG pharmacokinetics in obese and normal-weight women, but pharmacokinetics means how the body handles a substance; it is not the same as a weight-loss outcomes trial 11.
| Research area | What the supplied evidence includes | What it can and cannot answer |
|---|---|---|
| Frozen embryo transfer | Open-label randomized controlled trial in ovulatory women 1 | Can inform a specific assisted-reproduction research question; cannot answer weight-loss or general hormone-use questions |
| IVF and embryo transfer support | Randomized trial of hCG support after IVF and embryo transfer 5 | Can inform IVF-related research context; cannot be generalized to all fertility care |
| Ovulation induction | Randomized trials involving sublingual hCG and hCG with clomiphene citrate 3 4 | Can inform specific ovulation-induction protocols; cannot replace a clinician-directed fertility plan |
| Controlled ovarian stimulation | Randomized trial of low-dose hCG alone to complete controlled ovarian stimulation 7 | Can inform ovarian-stimulation research; cannot be converted into self-directed dosing |
| Male pharmacology | Randomized trial of recombinant and urinary hCG pharmacology in men 10 | Can inform formulation and pharmacology questions; cannot prove symptom outcomes for every man |
| Weight management | No supplied weight-loss outcomes trial | Does not support hCG as a weight-loss medication |
What studies exist
| Year | Design | Study | Journal | Record |
|---|---|---|---|---|
| 2024 | Randomised controlled trial | Livebirth rate after one frozen embryo transfer in ovulatory women starting with natural, modified natural, or artificial endometrial preparation in Viet Nam: an open-label randomi | Lancet (London, England) | PMID 38944045 |
| 1987 | Randomised controlled trial | Emergency contragestion | Contraception | PMID 2445524 |
| 2024 | Randomised controlled trial | Sublingual human chorionic gonadotropin as an adjuvant to ovulation induction | JBRA assisted reproduction | PMID 38224574 |
| 2024 | Randomised controlled trial | Competence of Combined Low Dose of Human Chorionic Gonadotropin (HCG) and Clomiphene Citrate (CC) Versus Continued CC during Ovulation Induction in Women with CC-Resistant Polycyst | Medicina (Kaunas, Lithuania) | PMID 39202581 |
| 1988 | Randomised controlled trial | A randomized trial of human chorionic gonadotropin support following in vitro fertilization and embryo transfer | Fertility and sterility | PMID 3277865 |
| 2020 | Clinical trial | Human chorionic gonadotropin promotes recruitment of regulatory T cells in endometrium by inducing chemokine CCL2 | Journal of reproductive immunology | PMID 31809964 |
| 2005 | Randomised controlled trial | Efficacy of low-dose human chorionic gonadotropin alone to complete controlled ovarian stimulation | Fertility and sterility | PMID 16084880 |
| 2018 | Clinical trial | Should intrauterine human chorionic gonadotropin infusions ever be used prior to embryo transfer? | Journal of assisted reproduction and genetics | PMID 28948440 |
| 1999 | Clinical trial | Preoperative treatment with human chorionic gonadotropin in infancy decreases the severity of proximal hypospadias and chordee | The Journal of urology | PMID 10492232 |
| 2024 | Randomised controlled trial | Single and multi-dose pharmacology of recombinant and urinary human chorionic gonadotrophin in men | Clinical endocrinology | PMID 38446525 |
| 2014 | Randomised controlled trial | Pharmacokinetics of human chorionic gonadotropin injection in obese and normal-weight women | The Journal of clinical endocrinology and metabolism | PMID 24476082 |
| 1999 | Clinical trial | Inverse relationship between serum inhibin B and FSH levels in prepubertal boys with cryptorchidism | Pediatric research | PMID 10541309 |
| Registration | Phase | Status | Enrolment | Title |
|---|---|---|---|---|
| NCT04064840 | PHASE3 | RECRUITING | 784 | GnRH Agonist for Dual Trigger in IVF and for Luteal Phase Support in FET |
| NCT01601327 | PHASE4 | COMPLETED | 119 | Effects of Medications in Patients With Hypogonadism |
| NCT05584397 | N/A | ENROLLING_BY_INVITATION | 40 | Comparing Immune Activation and Latent HIV Reservoir Size Between People Living With HIV on Tenofovir-containing Versus NRTI-free ART |
| NCT03252223 | PHASE4 | COMPLETED | 33 | Ovarian Response to Recombinant Follicle Stimulating Hormone in Women With PCOS |
| NCT02798146 | NA | COMPLETED | 20 | Early Luteal Progesterone Profile After hCG Triggering |
| NCT00702520 | N/A | COMPLETED | 15 | Pregnancy and Neonatal Follow-up of Ongoing Pregnancies Established in Clinical Trial 38833 (P05783) |
| NCT05473273 | N/A | RECRUITING | 40 | Descriptive Analysis of Serum Immunological Markers During an Euploid Frozen Embryo Transfer in a Natural Cycle. |
| NCT01279486 | N/A | COMPLETED | 120 | Clearblue Home Pregnancy Test Consumer Study |
This table is retrieved from PubMed and ClinicalTrials.gov rather than assembled by hand, so it shows what is indexed — including the absences. Last retrieved 2026-09-09.
Reported dosing ranges
hCG dosing is protocol-specific. The supplied PubMed records name several routes and formulations, including injection, urinary hCG, recombinant hCG, intrauterine infusion, and sublingual hCG, but the retrieved citation data provided here does not include numeric dosing ranges that can be safely reproduced as patient guidance 3 7 8 10 11.
That matters because hCG is studied in very different settings: embryo transfer, ovulation induction, controlled ovarian stimulation, pharmacokinetics, and male pharmacology 1 3 7 10 11. A dose used in one study context should not be copied into another context.
| Source | Population or setting | Route or formulation described | Reported dosing range available from supplied record? |
|---|---|---|---|
| Ho et al., 2024 1 | Frozen embryo transfer in ovulatory women | Endometrial preparation protocols | No numeric hCG dosing range available in the supplied record |
| Ferreira et al., 2024 3 | Ovulation induction | Sublingual human chorionic gonadotropin | No numeric hCG dosing range available in the supplied record |
| Thabet et al., 2024 4 | Clomiphene-resistant polycystic ovarian syndrome during ovulation induction | Combined low-dose hCG and clomiphene citrate | No numeric hCG dosing range available in the supplied record |
| Filicori et al., 2005 7 | Controlled ovarian stimulation | Low-dose hCG | No numeric hCG dosing range available in the supplied record |
| Volovsky et al., 2018 8 | Before embryo transfer | Intrauterine hCG infusion | No numeric hCG dosing range available in the supplied record |
| Handelsman et al., 2024 10 | Men in pharmacology research | Recombinant and urinary human chorionic gonadotrophin | No numeric hCG dosing range available in the supplied record |
| Shah et al., 2014 11 | Obese and normal-weight women in pharmacokinetic research | hCG injection | No numeric hCG dosing range available in the supplied record |
Legal status
Our regulatory log holds no confirmed federal action for hCG. That means we have not found one with a primary source — not that none exists.
This section is generated from a dated log of federal actions rather than written by hand, and it is re-checked daily against the Federal Register and FDA sources. Last checked 2026-09-09. See the full legal-status tracker for every compound we follow.
Safety
Safety with hCG depends on the reason it is being considered, the person’s sex, fertility status, dose, route, lab history, and other medications. The supplied studies span embryo transfer, ovulation induction, ovarian stimulation, pharmacokinetics, male pharmacology, and pediatric urology, so safety questions should be matched to the exact clinical context rather than treated as one general list 1 3 4 7 9 10 11.
In assisted reproduction, hCG may appear in protocols that also involve embryo transfer timing, ovarian stimulation, or ovulation induction medications such as clomiphene citrate 1 4 5 7. That is why the safety discussion often includes monitoring, cycle timing, ovarian response, pregnancy-related context, and the full fertility-medication plan.
For male hormonal-care questions, the supplied evidence supports only a pharmacology-focused discussion of recombinant and urinary hCG in men 10. It does not provide enough information to promise effects on symptoms, fertility, testosterone levels, or long-term risks for a specific person.
The supplied pediatric records are specialized and should not be generalized to adult hormone use. They include research in proximal hypospadias and chordee in infancy and biomarker research involving inhibin B and FSH in prepubertal boys with cryptorchidism 9 12.
Unregulated supply adds a separate safety problem. A “research use only” product is not the same as care through a clinician evaluation and a licensed pharmacy process; identity, sterility, impurity, storage, and handling are central safety questions for any product intended for human use.
If you are comparing online sellers, our guide on whether you can buy hCG peptide online explains why source, evaluation, and oversight matter. We also have region-specific education for people researching hCG in the UK or hCG in Australia.
Interactions
Interaction questions for hCG depend on the clinical setting. In the supplied evidence, hCG appears alongside fertility and reproductive protocols, including clomiphene citrate in a trial of women with clomiphene-resistant polycystic ovarian syndrome and ovarian-stimulation research 4 7.
The supplied evidence set does not include a dedicated drug-interaction study for hCG. That should not be read as proof of no interactions; it means the records provided here do not answer the interaction question in a complete way.
A careful evaluation should review fertility medications, hormone-related conditions, pregnancy-related context, prior lab results, and current prescriptions or supplements. This is especially important when hCG is being discussed with clomiphene citrate, letrozole, gonadotropins, testosterone-related concerns, or assisted reproductive technology protocols, because the supplied evidence spans those kinds of reproductive and hormone-response settings 1 4 7 10.
How to obtain it legally
The proper process starts with a clinician evaluation, not a research-chemical seller. A clinician can review your symptoms, goals, medical history, medication list, labs, fertility context, contraindications, and whether the evidence fits the reason you are asking.
- 1Start with the clinical question: fertility care, ovulation induction, male hormonal evaluation, or another specific concern.
- 2Bring a full medication and supplement list, including clomiphene citrate, letrozole, gonadotropins, testosterone-related treatments, and fertility medications if relevant.
- 3Review labs and reproductive history with a licensed clinician rather than using an online dosing calculator.
- 4Ask what route or formulation is being discussed and whether that matches published human evidence.
- 5Use a licensed pharmacy process when a clinician decides treatment is appropriate. A prescription is never guaranteed.
Chia does not offer hCG, and we do not prescribe, dispense, compound, or ship hCG. We do offer 100% online clinician-reviewed care for treatments listed in our live catalog, including GLP-1 weight management options, sermorelin, NAD+, glutathione, HRT for women, PT-141, GHK-Cu, and low-dose naltrexone.
For Chia-listed treatments, the process is a short online health questionnaire, review by a licensed US provider, provider-guided dosing when clinically appropriate, medication from US state-licensed 503A compounding pharmacies, and home delivery. Compounded medications are not FDA-approved, and a prescription requires a medical evaluation and is not guaranteed.
If your goal is adjacent to hCG rather than hCG itself, Chia may be relevant for care that we actually offer. For example, Chia offers tirzepatide tablets and injections and semaglutide injection for weight-management care when clinically appropriate, plus Sermorelin, NAD+, Glutathione, HRT for Women, and Low-Dose Naltrexone for listed care pathways.
Use Chia’s eligibility quiz only for Chia treatments listed in the live catalog, not for hCG access. If an AI agent helps organize your care, Chia can also be reached through DoctorMCP at mcp.chia.health for Chia-listed prescription delivery workflows.
| Goal someone may have | Does Chia offer hCG for this? | Chia-listed options that may be relevant instead |
|---|---|---|
| hCG-specific fertility or hormone question | No | Chia does not offer hCG |
| Weight management and metabolic health | No | Semaglutide injection from $249/mo; tirzepatide tablets from $249/mo and injections from $299/mo; microdosing plans available for both where clinically appropriate |
| Weight management plus energy support | No | Weight + Energy: NAD+ injection plus choice of GLP-1, from $309/mo |
| Weight management plus muscle-support goals | No | Weight + Muscle: Sermorelin injection plus choice of GLP-1, from $329/mo |
| Longevity-oriented care | No | Foundation Longevity: Sermorelin injection, NAD+ injection, and glutathione injection, from $399/mo |
| Women’s hormone care | No | HRT for Women: Estradiol Oral + Progesterone IR, from $119/mo |
hCG is discussed in male hormonal care because it has LH-like activity in reproductive hormone pathways. The supplied evidence includes a randomized pharmacology study of recombinant and urinary hCG in men, but it does not prove symptom benefits or define the right plan for any one person.
hCG, or human chorionic gonadotropin, is a hormone in the gonadotropin family. In the supplied studies, it is mainly discussed in fertility, ovulation induction, ovarian stimulation, endometrial signaling, pharmacokinetics, male pharmacology, and some pediatric urology research.
This page does not summarize legal status because that section is inserted separately. From a safety process standpoint, hormone-related care should start with a licensed clinician evaluation and, when appropriate, use a licensed pharmacy rather than a research-chemical seller.
Normal hCG levels depend on the clinical context, including pregnancy status, timing, the lab method, and why the test was ordered. A clinician should interpret hCG lab results with your history and the lab’s reference range.
The supplied evidence does not support hCG as a weight-loss medication. One supplied study looked at hCG pharmacokinetics in obese and normal-weight women, but pharmacokinetics is not the same as a weight-loss outcomes trial.
Pregnyl is a brand name commonly associated with human chorionic gonadotropin. hCG is the hormone name. The supplied evidence also refers to urinary hCG, recombinant hCG, injected hCG, intrauterine hCG infusion, and sublingual hCG in specific study settings.
Do not use an internet dosing chart as medical instructions. The supplied studies involve different populations, routes, and endpoints, so dosing must be tied to a clinician-reviewed protocol and individual risk review.
No. Chia does not offer hCG. Chia does offer clinician-reviewed care for listed treatments such as semaglutide, tirzepatide, sermorelin, NAD+, glutathione, GHK-Cu, PT-141, HRT for women, and low-dose naltrexone when clinically appropriate.
References
- 1.PMID 38944045 [randomised controlled trial] Ho VNA, Pham TD, Nguyen NT, et al. Livebirth rate after one frozen embryo transfer in ovulatory women starting with natural, modified natural, or artificial endometrial preparation in Viet Nam: an open-label randomised controlled trial. Lancet (London, England). 2024.
- 2.PMID 2445524 [randomised controlled trial] Schaison G. Emergency contragestion. Contraception. 1987.
- 3.PMID 38224574 [randomised controlled trial] Ferreira PAG, Giordano LA, Bittencourt LF. Sublingual human chorionic gonadotropin as an adjuvant to ovulation induction. JBRA assisted reproduction. 2024.
- 4.PMID 39202581 [randomised controlled trial] Thabet M, Abdelhafez MS, Elshamy MR, et al. Competence of Combined Low Dose of Human Chorionic Gonadotropin (HCG) and Clomiphene Citrate (CC) Versus Continued CC during Ovulation Induction in Women with CC-Resistant Polycystic Ovarian Syndrome: A Randomized Controlled Trial. Medicina (Kaunas, Lithuania). 2024.
- 5.PMID 3277865 [randomised controlled trial] Buvat J, Marcolin G, Herbaut JC, et al. A randomized trial of human chorionic gonadotropin support following in vitro fertilization and embryo transfer. Fertility and sterility. 1988.
- 6.PMID 31809964 [clinical trial] Huang X, Cai Y, Ding M, et al. Human chorionic gonadotropin promotes recruitment of regulatory T cells in endometrium by inducing chemokine CCL2. Journal of reproductive immunology. 2020.
- 7.PMID 16084880 [randomised controlled trial] Filicori M, Cognigni GE, Gamberini E, et al. Efficacy of low-dose human chorionic gonadotropin alone to complete controlled ovarian stimulation. Fertility and sterility. 2005.
- 8.PMID 28948440 [clinical trial] Volovsky M, Healey M, MacLachlan V, et al. Should intrauterine human chorionic gonadotropin infusions ever be used prior to embryo transfer?. Journal of assisted reproduction and genetics. 2018.
- 9.PMID 10492232 [clinical trial] Koff SA, Jayanthi VR. Preoperative treatment with human chorionic gonadotropin in infancy decreases the severity of proximal hypospadias and chordee. The Journal of urology. 1999.
- 10.PMID 38446525 [randomised controlled trial] Handelsman DJ, Idan A, Desai R, et al. Single and multi-dose pharmacology of recombinant and urinary human chorionic gonadotrophin in men. Clinical endocrinology. 2024.
- 11.PMID 24476082 [randomised controlled trial] Shah DK, Missmer SA, Correia KF, et al. Pharmacokinetics of human chorionic gonadotropin injection in obese and normal-weight women. The Journal of clinical endocrinology and metabolism. 2014.
- 12.PMID 10541309 [clinical trial] Raivio T, Dunkel L. Inverse relationship between serum inhibin B and FSH levels in prepubertal boys with cryptorchidism. Pediatric research. 1999.
About this article
Chia Health Editorial Team — Evidence-reviewed health education
This article is for educational purposes only and is not a substitute for individualized medical advice. Talk to a licensed clinician before starting, stopping, or changing any prescription.
AI tools may assist with research and drafting. Chia's editorial team reviews source use, clarity, treatment information, and safety framing before publication. A clinician is named only after explicit sign-off. Read our editorial standards.
Get a personalized plan
Find what fits your body and your goals.
Our 3-minute clinical quiz is reviewed by a US-licensed clinician. Treatment delivered to your door.
